Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Q3 2019 Earnings Conference Call - Final Transcript
Nov 06, 2019 • 05:00 pm ET
Good afternoon ladies and gentlemen. Thank you for standing by. And welcome to the Aerie Pharmaceuticals Third Quarter 2019 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to Aerie's Director of Investor Relations Ami Bavishi. Please go ahead Ami.
Thank you Sydney. Good afternoon and thank you for joining us. With me today are Vince Anido Chairman and Chief Executive Officer; Tom Mitro President and Chief Operation Officer; Rich Rubino Chief Financial Officer; Casey Kopczynski Chief Scientific Officer; and John LaRocca General Counsel. Today's call is also being webcast live on our website investors.aeriepharma.com and it will be available for replay as indicated in our press release. Before I review the forward-looking statements I want to ensure that you have access to the MOST Phase 4 top-line summary slides and Japan's Phase 2 summary slides that are available on our website and will be presented later during this call. Now for forward-looking statements and non-GAAP financial measures. On this call we will make certain forward-looking statements including statements forecasts and guidance regarding our future financial and operating performance including our updated full year 2019 net revenue guidance and full year net cash burn guidance.
These statements will include observations associated with our commercialization of Rhopressa and Rocklatan in the United States as well as recent top-line clinical data from our Phase 4 study in the U.S. and Phase 2 study in Japan. They will also include expectations regarding the success timing and cost of our clinical trials. Additionally we will discuss progress regarding maintaining requesting or obtaining approvals from regulatory agencies of our products and product candidates including our strategies and capabilities with respect to international expansion. Finally we will address our manufacturing activities and capabilities the potential of our pre-clinical product candidates and research findings our financial liquidity and other statements related to future events. These statements are based on the beliefs and expectations of management as of today.
Our actual results may differ materially from our expectations. Investors should read carefully the risks and uncertainties described in today's press release as well as the risk factors included in our filings with the SEC. We assume no obligation to revise or update forward-looking statements whether as a result of new information future events or otherwise. Please note that we will file our quarterly report on Form 10-Q tomorrow. In addition during this call we will be discussing certain adjusted or non-GAAP financial measures. For additional disclosures relating to these non-GAAP financial measures including a reconciliation to the most directly comparable GAAP measures please see today's press release which is posted on our website.
With that I will turn the call over to Vince.
Thanks Ami and good afternoon everybody. Thanks for joining us today. We obviously have quite a bit to talk about today in not only change in revenue guidance but also some exciting top-line clinical data that bodes pretty well for our long-term potential. So let's start with the update on